American Society of Hirudotherapy

Effectiveness of topical gel of medical leech (Hirudo medicinalis) saliva extract on patients with knee osteoarthritis: a randomized clinical trial

Shakouri A, Adljouy N, Balkani S, Mohamadi M, Hamishehkar H, Abdolalizadeh J, Kazem Shakouri S (2017) · Complementary Therapies in Clinical Practice · n=60

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Shakouri A 201760
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
randomized clinical trial of a leech-saliva-extract liposomal topical gel (Tabriz University of Medical Sciences, Iran)
Sample size (n)
60
Intervention
Topical liposome-based gel containing extracted Hirudo medicinalis saliva, applied to the symptomatic knee for 30 days
Comparator
Placebo gel (liposomal vehicle without leech saliva extract)
Primary endpoint
Pain on VAS and Lequesne index for knee OA at day 30
Primary result
After 30 days of leech-saliva liposomal gel, patient pain was reduced approximately 50% with concurrent reduction in joint inflammation and stiffness and improved range of motion and quality of life (p<0.001)
Follow-up duration
30 days

Key Findings

  • First RCT to test a leech-saliva-extract pharmaceutical formulation (vs. live leeches) for knee OA
  • Nano-liposomal encapsulation used to enhance transdermal absorption of leech salivary proteins
  • VAS pain reduction approximately 50% over 30 days vs. placebo gel
  • Improvements reported in Lequesne index, joint stiffness, and self-reported quality of life
  • Provides proof-of-concept for non-invasive leech-derived therapeutics as an alternative to live-animal application

Limitations

  • Single center (Tabriz University of Medical Sciences)
  • Short follow-up (30 days)
  • Salivary extract characterization and standardization not fully reported — batch-to-batch consistency unclear
  • No comparison with live leech therapy — cannot determine relative efficacy
  • Limited methodological detail on randomization and blinding in published report

Clinical Implications

Shakouri 2017 is a significant departure from the live-leech literature: instead of applying intact Hirudo medicinalis, the investigators extracted leech salivary proteins, encapsulated them in nano-liposomes, and applied them as a topical gel. This is the first RCT testing whether the active pharmacology of leech saliva can be delivered without the live-animal interface. For the ASH community, this is an important translational signal — though small and single-center, it suggests a pharmaceutical-grade leech-derived topical may eventually compete with live application for patients unwilling to undergo live-leech therapy. Clinicians should view this as exploratory until independent replication and full pharmacological characterization are available.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.